CRISPR-Mediated Kinome Editing Prioritizes a Synergistic Combination Therapy for FGFR1-Amplified Lung Cancer.

Fiche du document

Auteurs
Date

1 juin 2021

Type de document
Périmètre
Langue
Identifiants
Source

Serveur académique Lausannois

Relations

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1158/0008-5472.CAN-20-2276

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/33685992

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1538-7445

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_6D844130F3DD5

Collection

Serveur Académique Lausannois

Organisation

Université de Lausanne et CHUV

Licences

info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer

Mots-clés 0

Aged; Animals; Apoptosis; Benzamides/pharmacology; CRISPR-Cas Systems; Cell Cycle; Cell Cycle Proteins/antagonists & inhibitors; Cell Cycle Proteins/genetics; Cell Proliferation; Combined Modality Therapy; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms/genetics; Lung Neoplasms/metabolism; Lung Neoplasms/pathology; Lung Neoplasms/therapy; Male; Mice; Piperazines/pharmacology; Protein Kinase Inhibitors/pharmacology; Protein Serine-Threonine Kinases/antagonists & inhibitors; Protein Serine-Threonine Kinases/genetics; Proto-Oncogene Proteins/antagonists & inhibitors; Proto-Oncogene Proteins/genetics; Pyrazoles/pharmacology; Receptor, Fibroblast Growth Factor, Type 1/antagonists & inhibitors; Receptor, Fibroblast Growth Factor, Type 1/genetics; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

Sujets proches En

Lung

Citer ce document

Z. Yang et al., « CRISPR-Mediated Kinome Editing Prioritizes a Synergistic Combination Therapy for FGFR1-Amplified Lung Cancer. », Serveur académique Lausannois, ID : 10.1158/0008-5472.CAN-20-2276

Métriques

Partage / Export

Résumé 0

Oncogenic activation of the FGFR pathway is frequent in lung and other cancers. However, due to drug resistance, pharmacological blockage of aberrant FGFR signaling has provided little clinical benefit in patients with FGFR-amplified tumors. The determining factors for the limited efficacy of FGFR-targeted therapy remain incompletely understood. In this study, we performed kinome-wide CRISPR/Cas9 loss-of-function screens in FGFR1-amplified lung cancer cells treated with an FGFR inhibitor. These screens identified PLK1 as a potent synthetic lethal target that mediates a resistance mechanism by overriding DNA damage and cell-cycle arrest upon FGFR1 inhibition. Genetic and pharmacological antagonism of PLK1 in combination with FGFR inhibitor therapy synergized to enhance antiproliferative effects and drove cancer cell death in vitro and in vivo through activation of the γH2AX-CHK-E2F1 axis. These findings suggest a previously unappreciated role for PLK1 in modulating FGFR1 inhibitor sensitivity and demonstrate a synergistic drug combination for treating FGFR1-amplified lung cancer. SIGNIFICANCE: The identification of PLK1 as a potent synthetic lethal target for FGFR-targeted therapy provides an innovative rationale for the treatment of lung and other FGFR1-amplified cancers.

document thumbnail

Par les mêmes auteurs

Sur les mêmes sujets

Exporter en